Andrea Botticelli
Overview
Explore the profile of Andrea Botticelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
155
Citations
2299
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Imbimbo G, Pellegrini M, Scagnoli S, Pisegna S, Rizzo V, Gallicchio C, et al.
Clin Nutr
. 2025 Mar;
47:242-247.
PMID: 40054028
Background & Aims: Nowadays, limited data or no data are available on body composition changes and the development of treatment-related toxicities in metastatic breast cancer (MBC) patients treated with innovative...
2.
Berton Giachetti P, Morganti S, Gandini S, Giudici F, Marra A, Nicolo E, et al.
JAMA Netw Open
. 2025 Feb;
8(2):e2461067.
PMID: 39982725
Importance: Endocrine therapy (ET) combined with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) agents is the standard first-line treatment for patients with hormone receptor-positive, ERBB2 (formerly HER2 or HER2/neu)-negative metastatic breast cancer....
3.
Fabi A, Rossi A, Caputo R, Pisegna S, Scagnoli S, Pantano F, et al.
NPJ Precis Oncol
. 2025 Jan;
9(1):22.
PMID: 39843642
Tumor dissemination to the central nervous system (CNS) is almost a rule in the treatment journey of advanced HER2+ breast cancer (BC). Recent results demonstrated high intracranial efficacy with Trastuzumab...
4.
Krasniqi E, Filomeno L, Arcuri T, Di Lisa F, Astone A, Cutigni C, et al.
Cancers (Basel)
. 2024 Dec;
16(23).
PMID: 39682290
Background/objectives: HER2-positive breast cancer (HER2BC) is an aggressive subtype, with neoadjuvant treatment (NAT) aiming to achieve a pathological complete response (pCR) to improve long-term outcomes. Trastuzumab emtansine (T-DM1) has been...
5.
Filetti M, Occhipinti M, Cirillo A, Scirocchi F, Ugolini A, Giusti R, et al.
Cancers (Basel)
. 2024 Dec;
16(23).
PMID: 39682144
: Single-agent immune checkpoint inhibitor (IO) therapy is the standard for non-oncogene-addicted advanced non-small cell lung cancer (aNSCLC) with PD-L1 tumor proportion score ≥ 50%. Smoking-induced harm generates high tumor...
6.
Baldelli R, Franco M, Renzelli V, DE Fata R, Visca P, Macciomei M, et al.
Minerva Endocrinol (Torino)
. 2024 Dec;
PMID: 39660883
Background: The aim of our retrospective study was to describe the immunophenotypic characteristics of neuroendocrine breast neoplasm (BNEN), a peculiar and rare type of breast carcinoma. Methods: Pathological data from...
7.
Scagnoli S, Pisegna S, Toss A, Caputo R, De Laurentiis M, Palleschi M, et al.
NPJ Breast Cancer
. 2024 Aug;
10(1):68.
PMID: 39095493
No abstract available.
8.
Scagnoli S, Pisegna S, Toss A, Caputo R, De Laurentiis M, Palleschi M, et al.
NPJ Breast Cancer
. 2024 Jul;
10(1):58.
PMID: 39019916
Abemaciclib demonstrated clinical benefit in women affected by HR+/HER2- advanced breast cancer (aBC). Drug-drug interactions (DDIs) can lead to reduced treatment efficacy or increased toxicity. This retro-prospective study aimed to...
9.
Botticelli A, Cirillo A, dAmati G, Di Gioia C, Corsi A, Della Rocca C, et al.
Pathol Res Pract
. 2024 Jul;
260:155415.
PMID: 38996615
Immunotherapy has a crucial role in the treatment of recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). However, only a small percentage of patients achieve long-term benefit in terms...
10.
Santamaria F, Roberto M, Buccilli D, Di Civita M, Giancontieri P, Maltese G, et al.
Crit Rev Oncol Hematol
. 2024 Jun;
200:104405.
PMID: 38838928
In the last two-decades, innovative drugs have revolutionized cancer treatments, demonstrating a significant improvement in overall survival. These drugs may present several pharmacokinetics interactions with non-oncological drugs, and vice versa,...